DE69431717D1 - BEHANDLUNG MITTELS EISEN-ENTZUG KOMBINIERT MIT IgG ANTIKÖRPER - Google Patents

BEHANDLUNG MITTELS EISEN-ENTZUG KOMBINIERT MIT IgG ANTIKÖRPER

Info

Publication number
DE69431717D1
DE69431717D1 DE69431717T DE69431717T DE69431717D1 DE 69431717 D1 DE69431717 D1 DE 69431717D1 DE 69431717 T DE69431717 T DE 69431717T DE 69431717 T DE69431717 T DE 69431717T DE 69431717 D1 DE69431717 D1 DE 69431717D1
Authority
DE
Germany
Prior art keywords
treatment
igg antibody
tumor cells
combined
iron
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69431717T
Other languages
English (en)
Other versions
DE69431717T2 (de
Inventor
John D Kemp
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Iowa Research Foundation UIRF
Original Assignee
University of Iowa Research Foundation UIRF
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Iowa Research Foundation UIRF filed Critical University of Iowa Research Foundation UIRF
Publication of DE69431717D1 publication Critical patent/DE69431717D1/de
Application granted granted Critical
Publication of DE69431717T2 publication Critical patent/DE69431717T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE69431717T 1993-04-29 1994-01-25 BEHANDLUNG MITTELS EISEN-ENTZUG KOMBINIERT MIT IgG ANTIKÖRPER Expired - Fee Related DE69431717T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5467993A 1993-04-29 1993-04-29
PCT/US1994/000911 WO1994025066A1 (en) 1993-04-29 1994-01-25 COMBINED TREATMENT OF IRON DEPLETION AND IgG ANTIBODY

Publications (2)

Publication Number Publication Date
DE69431717D1 true DE69431717D1 (de) 2002-12-19
DE69431717T2 DE69431717T2 (de) 2003-09-18

Family

ID=21992780

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69431717T Expired - Fee Related DE69431717T2 (de) 1993-04-29 1994-01-25 BEHANDLUNG MITTELS EISEN-ENTZUG KOMBINIERT MIT IgG ANTIKÖRPER

Country Status (10)

Country Link
EP (1) EP0697889B1 (de)
JP (1) JPH09500868A (de)
AT (1) ATE227585T1 (de)
AU (1) AU699915B2 (de)
CA (1) CA2161656A1 (de)
DE (1) DE69431717T2 (de)
DK (1) DK0697889T3 (de)
ES (1) ES2187521T3 (de)
PT (1) PT697889E (de)
WO (1) WO1994025066A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2426098T3 (es) * 2009-07-16 2013-10-21 Institut National de la Santé et de la Recherche Médicale Composiciones farmacéuticas y su uso en el tratamiento del cáncer
WO2020127885A1 (en) * 2018-12-21 2020-06-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions for treating cancers and resistant cancers
CN114217071B (zh) * 2021-12-01 2023-11-14 柏荣诊断产品（上海）有限公司 一种高特异性透散射一体法铁蛋白胶乳比浊检测试剂盒

Also Published As

Publication number Publication date
EP0697889A1 (de) 1996-02-28
DE69431717T2 (de) 2003-09-18
DK0697889T3 (da) 2003-03-17
JPH09500868A (ja) 1997-01-28
EP0697889A4 (de) 1997-01-02
WO1994025066A1 (en) 1994-11-10
EP0697889B1 (de) 2002-11-13
CA2161656A1 (en) 1994-11-10
AU699915B2 (en) 1998-12-17
ATE227585T1 (de) 2002-11-15
AU6586094A (en) 1994-11-21
ES2187521T3 (es) 2003-06-16
PT697889E (pt) 2003-03-31

Similar Documents

Publication Publication Date Title
DE69221147D1 (de) Nicht glycosylierter Anti-CD3-IgG-Antikörper
JPS6447378A (en) Monoclonal antibody to black tumor related antigen, hybrid cell line for producing the same and use thereof
DE3382474D1 (de) Menschliche monoklonale antikoerper gegen bakterielle toxine.
HUT72914A (en) Monoclonal, chimeric, radiolabeled antibodies to the b cell sorface antigen bp 35 ("cd20"), hybridoma cells producing monoclonal antibodies and application of antibodies for treatment of b cell lymphoma
IL80231A (en) Monoclonal anti-human breast cancer antibodies and hybridomas producing them,and diagnosis of human breast tumors
ES8706964A1 (es) Un procedimiento para fraccionar anticuerpos de suero.
FI963004A0 (fi) Vasta-aineen muodostumista kiihottavia monoklonaalivasta-aineita
UA50708C2 (uk) Моноклональне антитіло, яке має здатність розпізнавати антиген, який викликає апоптоз мієлоїдних клітин, фрагмент f(ab)2 моноклонального антитіла, гібридома ferm bp-4382
MY106561A (en) Method of making factor-dependent human b cell lines
MY135673A (en) Monoclonal antibodies for inducing tolerance
GR3031518T3 (en) Selective system scan for multizone radiotelephone subscriber units.
DE3684211D1 (de)
YU306680A (en) Method of obtaining monoclonal antibodies
EP0352722A3 (de) Bindungstests für Adenocarcinoma-Antigen und Reagenzien
EP0351045A3 (de) Monoklonaler Antikörper NUH2, der das Spermabewegungsvermögen inaktivieren kann, von diesem monoklonalen Antikörper bestimmtes Antigen und Methoden zur Verwendung dieses monoklonalen Antikörpers und Antigens
DE69431717D1 (de) BEHANDLUNG MITTELS EISEN-ENTZUG KOMBINIERT MIT IgG ANTIKÖRPER
DE69015230D1 (de) Antikörper gegen menschliches Sperma, ihre Herstellung und Anwendung.
ATE283927T1 (de) Monoklonale antikörper und antigene mit bezug zum menschlichen lungenadenokarzinom und immunoassay- verfahren unter verwendung desselben
PT733903E (pt) Processo de dosagem imunologica de cortisol nomeadamente urinario e reagentes utilizados
ATE74382T1 (de) Monoklonaler antikoerper, spezifisch fuer brustkrebszelloberflaechenantigen.
EP0184370A3 (de) Für ein zytoplasmisches Antigen eines Brusttumors spezifischer monoklonaler Antikörper
ATE274920T1 (de) Verwendung von anti-il-12 antikörpern bei transplantationsabstossungen
ATE97324T1 (de) Verwendung von amphipatischen molekuelen zur radiodarstellung und therapie mittels monoklonaler oder polyklonaler antikoerperkonjugate.
WO1987007302A3 (en) MONOCLONAL ANTIBODIES TO HUMAN LYMPHOCYTE IgE RECEPTORS, HYBRIDOMAS PRODUCING SUCH ANTIBODIES, AND KITS FOR USING SUCH ANTIBODIES
FR2621127B1 (fr) Anticorps monoclonal reconnaissant un epitope de la chaine gamma des recepteurs de surface des cellules t humaines, lignee de cellules d'hybridomes produisant cet anticorps, et utilisation de cet anticorps monoclonal

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee